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Abstract: Cancer-associated retinopathy (CAR) is an uncommon paraneoplastic retinopathy usually associated with 
small cell lung carcinoma. To our knowledge, there is no previous report in the English literature of CAR syndrome 
occurring in lymphoma patients. We describe a rare case of CAR syndrome in a 62-year-old male with non-Hodgkin’s 
lymphoma (NHL) treated with four doses of intravenous immunoglobulin. 
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INTRODUCTION 
 
Paraneoplastic neurologic syndromes are a group 
of neurologic disorders caused by mechanisms other 
than metastases. Metabolic deficit, infections and the 
side effects of chemotherapy are all possible causes of 
these disorders. One such syndrome in this group is 
the paraneoplastic visual syndrome comprising cancer- 
associated retinopathy (CAR), melanoma-associated 
retinopathy (MAR), and paraneoplastic optic 
neuropathy [1]. The CAR syndrome is uncommon and 
usually associated with small cell lung carcinoma [2, 3]. 
We report, to our knowledge, the first case in the 
English literature of CAR syndrome occurring in a 
patient with non-Hodgkin’s lymphoma and treated with 
intravenous  immunoglobulin. 
 
CASE REPORT 
 
A 62-year-old male was diagnosed with stage IV, B- 
cell follicular non-Hodgkin’s lymphoma, and he was 
treated with six cycles of rituximab and conventional 
chemotherapy (R-CHOP).  Five weeks after the last 
cycle, he presented with progressive decrease of vision 
in both eyes, flickering lights and night blindness, over 
a two weeks period. Laboratory tests showed a low 
hemoglobin level (10.2 g/dL), elevated total serum 
protein (11.8 g/dL), lactate dehydrogenase (305 IU/L) 
and creatinine level (2.3 mg/dL). Serum IgG level was 
increased   to   8760   mg/dL   (nl.   564-1765).   On 
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examination, corrected visual acuity was 20/80 and 
20/100 in the right and left eye, respectively. The pupils 
were equal in size and reactive to light and near 
accommodation, extra-ocular movements were full 
without nystagmus, and color vision by the Ishihara 
method was diminished bilaterally. Intraocular pressure 
was within the normal limits in both eyes. Fundus 
examination revealed pallor of the optic disks while 
visual field examination showed profound field 
constriction. Magnetic resonance imaging of the head 
and orbits showed no signs of metastases or other 
abnormalities. 
 
We initially performed visual evoked potentials, 
which were diffusely abnormal, but not diagnostic. A 
multi-focal electroretinogram (ERG) revealed 
dysfunction of both rods and cones characteristic of 
diffuse photoreceptor degeneration, which is supporting 
the diagnosis of CAR syndrome. Western blot analysis 
of the patient’s serum showed a positive antibody 
reaction with 23-kDa component coinciding with the 
molecular mass of human recoverin. 
 
The patient was started on oral prednisone 60 mg 
daily. However, three weeks later he still complained of 
decreased vision in both eyes. Intravenous 
immunoglobulin (400 mg/kg/day) was given for four 
doses. Following the second dose, the patient showed 
signs of improvement. Four weeks after finishing the 
full treatment, visual acuity improved to 20/40 in both 
eyes, with no relapse during 8 months follow up period. 
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DISCUSSION 
 
Ocular involvement in NHL lymphoma is rare and 
can be classified clinically into two major groups: 1- 
primary ocular NHL and 2- systemic NHL with 
secondary metastatic ocular involvement [4]. Primary 
ocular NHL usually presents as chronic vitritis that dose 
not respond to topical steroid treatment [4, 5]; Such 
primary ocular NHL is generally associated with central 
nervous system involvement by NHL later in the course 
of the disease [6]. 
 
The second group, which occurs more frequently, 
consists of ocular involvement in systemic NHL, as a 
result of metastatic spread of the lymphoma to the 
choroid or the anterior chamber [7, 8]. In addition, there 
are occasional reports of optic nerve neuropathy or 
infiltration by lymphoma [9-11]. Finally, and very rarely, 
there may be a lymphoma stimulated uveitis in the 
absence of metastases [12]. 
 
To our knowledge, there has been only one 
previous report (in the French literature) of CAR 
syndrome in lymphoma patients. Matus et al. described 
two NHL patients with symptoms of CAR, which was 
confirmed by the presence of anti-reoverin antibodies. 
Both cases were treated by corticosteroids with only 
minimal response [13]. 
 
Patients with CAR develop symptoms related to 
dysfunction of both cones (photosensitivity, abnormal 
visual acuity, color vision abnormalities, central 
scotomata) and/or rods (nyctalopia or night blindness, 
prolonged dark adaptation, peripheral or ring-like 
scotomata), and the ERG is extremely helpful in the 
diagnosis of CAR syndrome [14, 15]. Fifteen different 
antigens have been described in association with CAR. 
However, the only characteristic paraneoplastic marker 
is the presence of antibodies against recoverin [16, 17] 
and the a-enolase [18]. Recoverin is a retina-specific 
calcium binding protein that is expressed in 
photoreceptors and retinal bipolar cells [19]. The 
discovery of anti-recoverin antibodies in CAR patients’ 
serum led to the hypothesis that the retinal 
degeneration that occurs in this syndrome is caused by 
the recoverin-specific antibodies reacting with the 
retinal tissue [20, 21]. Interestingly, a group of patients 
with anti-recoverin antibodies has been identified 
without any malignancy; these patients presented 
similar progressive visual loss, retinal degeneration and 
ERG changes as did CAR patients [22]. 
Since CAR syndrome is a rare condition, no specific 
treatment has been shown to be effective, and the 
visual prognosis is usually poor [23]. Treating the 
underlining malignancy has not been shown to result in 
better visual outcomes [24] and immuno-suppression 
with oral or intravenous corticosteroid exhibits only a 
transient or undetectable response [13, 25]. 
Furthermore, plasmapheresis has not been effective 
[22]. Finally, intravenous immunoglobulin (IVIG) 
therapy has also been employed with various results; 
improvement of visual acuity and fields was noted in 
one patient, improvement of visual fields only in a 
second patient, and no effect in the third [26, 27]. 
However, our patient showed significant improvement 
after four cycles of treatment with IVIG. 
 
Conclusion: CAR may occur in NHL as well as the 
more common small cell cancer and other 
malignancies. Intravenous immunoglobulin may be an 
effective option for treating these patients, especially if 
started early enough before permanent retinal damage 
occurs. The results of present case represent the 
potential use of IVIG in this condition. 
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